BRPI0821302A2 - Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto - Google Patents

Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto

Info

Publication number
BRPI0821302A2
BRPI0821302A2 BRPI0821302-0A BRPI0821302A BRPI0821302A2 BR PI0821302 A2 BRPI0821302 A2 BR PI0821302A2 BR PI0821302 A BRPI0821302 A BR PI0821302A BR PI0821302 A2 BRPI0821302 A2 BR PI0821302A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
inflammatory bowel
preventing
treating inflammatory
compound
Prior art date
Application number
BRPI0821302-0A
Other languages
English (en)
Inventor
Tomohisa Ninomiya
Mitsuhiro Uchida
Sho Takahata
Yukari Hoshina
Ken-Ichi Kawano
Takashi Shishikura
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BRPI0821302A2 publication Critical patent/BRPI0821302A2/pt
Publication of BRPI0821302A8 publication Critical patent/BRPI0821302A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0821302A 2007-12-18 2008-12-17 Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto BRPI0821302A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007326543 2007-12-18
PCT/JP2008/072999 WO2009078444A1 (ja) 2007-12-18 2008-12-17 炎症性腸疾患の予防または治療剤

Publications (2)

Publication Number Publication Date
BRPI0821302A2 true BRPI0821302A2 (pt) 2015-06-16
BRPI0821302A8 BRPI0821302A8 (pt) 2015-12-08

Family

ID=40795557

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821302A BRPI0821302A8 (pt) 2007-12-18 2008-12-17 Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto

Country Status (16)

Country Link
US (1) US7858612B2 (pt)
EP (1) EP2123277B1 (pt)
JP (1) JP4343268B2 (pt)
KR (1) KR101216756B1 (pt)
CN (1) CN101903027B (pt)
AT (1) ATE497386T1 (pt)
AU (1) AU2008339393A1 (pt)
BR (1) BRPI0821302A8 (pt)
CA (1) CA2709119C (pt)
DE (1) DE602008004820D1 (pt)
DK (1) DK2123277T3 (pt)
ES (1) ES2360461T3 (pt)
PL (1) PL2123277T3 (pt)
PT (1) PT2123277E (pt)
RU (1) RU2469724C2 (pt)
WO (1) WO2009078444A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315370B (zh) 2018-07-28 2023-09-29 苏州沪云新药研发股份有限公司 一种具有抗炎症性肠病作用的药物及其制备方法和应用
EP3836912B1 (en) * 2018-08-15 2024-05-01 Pharmacyl AB Combinations of substituted benzamides and 5-asa agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637654A5 (en) * 1977-02-18 1983-08-15 Takeda Chemical Industries Ltd Triazolobenzazepine derivatives, process for their preparation and pharmaceutical preparations containing them
DE69427023T2 (de) * 1993-12-28 2001-10-31 Meiji Seika K.K., Tokio/Tokyo Tricyclische benzazepin-und benzothiazepin derivate
JP3537446B2 (ja) 1995-06-15 2004-06-14 明治製菓株式会社 三環性ベンゾアゼピン化合物
ES2191963T3 (es) 1997-09-29 2003-09-16 Meiji Seika Kaisha Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
PE20001566A1 (es) * 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
JP4323802B2 (ja) 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
ATE469902T1 (de) * 2001-12-26 2010-06-15 Meiji Seika Kaisha Amorphe substanz eines tricyclischen triazolobenzazepinderivats
EP1650266A1 (en) * 2003-06-20 2006-04-26 Meiji Seika Kaisha Ltd. Product of coprecipitation of sparingly soluble substance and water-soluble polymer and process for producing the same
JP2007326543A (ja) 2006-06-07 2007-12-20 Giichi Ishikura 排気ガス利用による保温ダンプ

Also Published As

Publication number Publication date
PL2123277T3 (pl) 2011-08-31
CA2709119C (en) 2013-08-06
CA2709119A1 (en) 2009-06-25
WO2009078444A1 (ja) 2009-06-25
PT2123277E (pt) 2011-04-20
US20100130475A1 (en) 2010-05-27
AU2008339393A1 (en) 2009-06-25
EP2123277A4 (en) 2010-01-06
BRPI0821302A8 (pt) 2015-12-08
RU2010129447A (ru) 2012-01-27
DK2123277T3 (da) 2011-03-14
EP2123277A1 (en) 2009-11-25
CN101903027A (zh) 2010-12-01
ES2360461T3 (es) 2011-06-06
JPWO2009078444A1 (ja) 2011-04-28
US7858612B2 (en) 2010-12-28
ATE497386T1 (de) 2011-02-15
JP4343268B2 (ja) 2009-10-14
KR101216756B1 (ko) 2012-12-28
KR20100094576A (ko) 2010-08-26
CN101903027B (zh) 2013-06-12
DE602008004820D1 (de) 2011-03-17
RU2469724C2 (ru) 2012-12-20
EP2123277B1 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
WO2008079291A3 (en) Substituted heterocycles and methods of use
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
ECSP088923A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
LU92602I2 (fr) Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
WO2002066480A3 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
BRPI0408858A (pt) uso de um inibidor de ibat ou, um sal, solvato, solvato de um tal sal ou uma pró-droga destes, farmaceuticamente aceitáveis, composição farmacêutica, e, método de tratamento e/ou profilaxia de constipação em um animal de sangue quente
WO2009143211A3 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
WO2005070891A3 (en) Compounds and methods of use
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
WO2008046084A3 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
NO20072046L (no) Halogensubstituerte benzodiazepinderivater
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
TW200745130A (en) 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
WO2007061692A3 (en) Spirolactam tricyclic cgrp receptor antagonists
TW200735878A (en) Pharmaceutical compositions
BRPI0821302A2 (pt) Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto
WO2005107752A3 (en) Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B25D Requested change of name of applicant approved

Owner name: MEIJI SEIKA PHARMA CO., LTD. (JP)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.